Possible treatment for COVID-19 related respiratory failure

Guest: Jonathan C. Javitt, CEO, NeuroRx

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at Clarivate, speaks with Jonathan Javitt, CEO of NeuroRx. Dr Javitt discusses how NeuroRx is working in collaboration with Relief Therapeutics on Aviptadil, a synthetic version of vasoactive intestinal peptide, and a potential treatment of COVID-19 related respiratory failure. Dr. Javitt shares the promising results of an open label study of the drug, and the company’s plans if trials are successful. Watch the episode now to learn more.

About our guest

  • Jonathan C. Javitt
  • CEO
  • NeuroRx

Dr. Javitt has played leadership roles in seven successful healthcare IT and biopharma startups with public exits. He has additionally led drug-development engagements for Merck, Allergan, Pharmacia, Novartis, and Pfizer. He was appointed to healthcare leadership roles under Presidents Reagan, George H.W. Bush, Clinton, and George W. Bush. In the latter role he was commissioned to lead the White House policy for universal adoption of Health IT and establishment of the Office of the National Coordinator. He is a graduate of Princeton University, Cornell University Medical College, Harvard School of Public Health, the Wills Eye Hospital, and Johns Hopkins Medical School. Dr. Javitt has published more than 200 scientific works in the areas of health outcomes and pharmacoeconomics that have been cited by more than 16,000 people.

About our host

  • Mike Ward
  • Head of Thought Leadership
  • Clarivate

Mike Ward serves as Global Head of Thought Leadership at Clarivate. As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. He has held editorial and content leadership roles at various publications and organizations across the industry.

Got a question?

If you have a question for our guest, host or Clarivate please submit it here.